Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant HAIC + Tislelizumab + Lenvatinib for HCC
NCT06311916Phase 4Not yet recruiting
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of tislelizumab and lenvatinib in hepatocellular carcinoma (HCC). Primary endpoint: Disease-free survival at 60 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06311916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311916.